𝐑𝐚𝐩𝐢𝐝 𝐟𝐢𝐫𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐧 𝐕𝐢𝐧𝐚𝐲 𝐏𝐫𝐚𝐬𝐚𝐝’𝐬 𝐝𝐞𝐩𝐚𝐫𝐭𝐮𝐫𝐞 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐅𝐃𝐀:

The recent departure of Vinay Prasad from the FDA, following controversy over Sarepta Therapeutics’ gene therapy Elevidys, underscores the complex risks that family offices can face when making mission driven biopharma investments.

Prasad, a vocal critic of accelerated approvals, left the FDA after spearheading a crackdown on Elevidys, prompted by three patient deaths linked to acute liver failure. Political pressure from this decision in addition to Prasad’s previous positions on vaccine administration led to him stepping down. This suggests internal or political pressures within the FDA, highlighting how regulatory decisions will pivot on leadership dynamics over the coming years.

The volatility where regulatory decisions reflect political priorities poses risks for family offices. A single leadership change or policy shift can derail a promising investment, as seen with Sarepta’s 86% share plunge in the last 6 months.

For family offices, biopharma’s allure lies in its potential for transformative impact. In our experience, investment decisions are often made due to deeply personal or altruistic aims. Yet, the Sarepta case underscores the need for a nuanced approach. We guide our clients to navigate these complexities—science, regulation, reimbursement, and politics—using our expert team and AI powered analysis to craft bespoke strategies that mitigate risk and seize opportunity. What’s your view on balancing impact and volatility in biopharma?